UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 89

Sortiert nach

Pembrolizumab plus lenalidomide and dexamethasone in treatment-naive multiple myeloma (KEYNOTE-185): subgroup analysis in Japanese patients

International journal of hematology, 2020-11, Vol.112 (5), p.640-649

2020

Link zum Volltext

Verfügbarkeit prüfen

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis of the Phase 3 Candor Study in Patients with Early or Late Relapse

Blood, 2020-11, Vol.136 (Supplement 1), p.37-38

2020

Link zum Volltext

Verfügbarkeit prüfen

Case of Angioimmunoblastic T-cell Lymphoma Presenting as a Methotrexate-associated Lymphoproliferative Disorder with Extreme Peripheral Blood Plasmacytosis

Internal Medicine, 2022, pp.8422-21

2022

Link zum Volltext

Verfügbarkeit prüfen

Elotuzumab Plus Pomalidomide/Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Japanese Subanalysis of the Randomized Phase 2 Eloquent-3 Study

Blood, 2018-11, Vol.132 (Supplement 1), p.3260-3260

2018

Link zum Volltext

Verfügbarkeit prüfen

Treatment strategy in untreated transplant-eligible multiple myeloma patients

Rinshō ketsueki, 2016, Vol.57 (10), p.2064

Sunami, Kazutaka

2016

Link zum Volltext

Verfügbarkeit prüfen

OPTIMISMM Japanese Subgroup Analysis: Pomalidomide, Bortezomib, and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Clinical lymphoma, myeloma and leukemia, 2019-10, Vol.19 (10), p.e270-e271

2019

Link zum Volltext

Verfügbarkeit prüfen

Safety and Efficacy of Elotuzumab with Lenalidomide/Dexamethasone for Multiple Myeloma in a Japanese Subpopulation Analysis of the Phase 3 Eloquent-2 Trial

Blood, 2016-12, Vol.128 (22), p.3315-3315

2016

Link zum Volltext

Verfügbarkeit prüfen

Antileukemic

Nihon rinshō, 2015-02, Vol.73 Suppl 2, p.191

2015

Link zum Volltext

Verfügbarkeit prüfen

Improved survival outcomes and relative youthfulness of multiple myeloma patients with t(4;14) receiving novel agents are associated with poorer performance of the revised international staging system in a real aging society

Oncotarget, 2019-01, Vol.10 (5), p.595-605

2019

Link zum Volltext

Verfügbarkeit prüfen

Proposal of Progressive Adult Onset EBV-Associated Lymphoproliferative Disorder (PAEBV) as a Rapid-Onset Neoplastic Disease

Blood, 2009-11, Vol.114 (22), p.2920-2920

2009

Link zum Volltext

Verfügbarkeit prüfen

Characteristics and Risk for Progression of Smoldering Multiple Myeloma: Japanese Nationwide Retrospective Survey

Annals of oncology, 2014-10, Vol.25, p.v60

2014

Link zum Volltext

Verfügbarkeit prüfen

MM-004: A Phase 1, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, Efficacy, and Pharmacokinetics of Pomalidomide Alone or in Combination with Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma in Japan

Blood, 2014-12, Vol.124 (21), p.2107-2107

2014

Link zum Volltext

Verfügbarkeit prüfen

Elranatamab in Combination with Daratumumab for Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 3 Magnetismm-5 Study Safety Lead-in Cohort

Blood, 2022-11, Vol.140 (Supplement 1), p.4407-4408

2022

Link zum Volltext

Verfügbarkeit prüfen

Subcutaneous Isatuximab Administration By an on-Body Delivery System (OBDS) in Combination with Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Phase 1b Expansion Study Results

Blood, 2022-11, Vol.140 (Supplement 1), p.4412-4414

2022

Link zum Volltext

Verfügbarkeit prüfen

Subcutaneous (SC) isatuximab administration by an on-body delivery system (OBDS) in combination with pomalidomide-dexamethasone (Pd) in patients with relapsed/refractory multiple myeloma (RRMM): Interim phase 1b study results

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.8025-8025

2022

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of the Revised International Staging System in 400 Patients with Symptomatic Myeloma in a Japanese Clinical Setting

Blood, 2018-11, Vol.132 (Supplement 1), p.4477-4477

2018

Link zum Volltext

Verfügbarkeit prüfen

Clinical Impact of Cell-of-Origin and Double-Hit Signature of DLBCL in Japan

Blood, 2022-11, Vol.140 (Supplement 1), p.6421-6423

2022

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Zanubrutinib in Japanese Patients with Mature B-Cell Malignancies

Blood, 2022-11, Vol.140 (Supplement 1), p.3663-3665

2022

Link zum Volltext

Verfügbarkeit prüfen

Impact of Continuous and Maintenance Therapy on Survival Outcome in Patients with Newly Diagnosed Multiple Myeloma: A Multicenter Retrospective Collaborative Study of the Japanese Society of Myeloma

Blood, 2019-11, Vol.134 (Supplement_1), p.3085-3085

2019

Link zum Volltext

Verfügbarkeit prüfen

P-306 Final results of a Phase 1b study of subcutaneous isatuximab administration by an on-body delivery system (OBDS) plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma (RRMM)

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S206-S207

2023

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of Isatuximab with Pomalidomide and Dexamethasone in Elderly Patients with Relapsed/Refractory Multiple Myeloma: Icaria-MM Subgroup Analysis

Blood, 2019-11, Vol.134 (Supplement_1), p.1893-1893

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 89

Suche als RSS-Feed

Aktive Filter

ThemaMultiple Myeloma - Drug Therapy

ThemaLife Sciences & Biomedicine

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(81)
Mit Volltextzugriff
(84)

Publikationsform

Artikel
(89)

Sprache

Englisch
(82)
Japanisch
(12)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(41)
Clinical Lymphoma, Myeloma And Leukemia
(8)
Cancer Science
(4)
Journal Of Cardiac Failure
(4)
Journal Of Clinical Oncology
(3)
Rinsho Ketsueki
(3)
Rinshō Ketsueki
(3)
Solid State Commun
(3)
Solid State Communications
(3)
Ejhaem
(2)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Pembrolizumab plus lenalidomide and dexamethasone in treatment-naive multiple myeloma (KEYNOTE-185): subgroup analysis in Japanese patients

P929: CIRCULATING TUMOR DNA ASSESSMENT IMPROVES PROGNOSTIC PREDICTION IN RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING IXAZOMIB, LENALIDOMIDE, AND DEXAMETHASONE

Outcomes of poor peripheral blood stem cell mobilizers with multiple myeloma at the first mobilization: A multicenter retrospective study in Japan

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis of the Phase 3 Candor Study in Patients with Early or Late Relapse

Phase II study of dose‐adjusted gemcitabine, dexamethasone, cisplatin, and rituximab in elderly relapsed diffuse large B‐cell lymphoma patients

Case of Angioimmunoblastic T-cell Lymphoma Presenting as a Methotrexate-associated Lymphoproliferative Disorder with Extreme Peripheral Blood Plasmacytosis

Elotuzumab Plus Pomalidomide/Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Japanese Subanalysis of the Randomized Phase 2 Eloquent-3 Study

Treatment strategy in untreated transplant-eligible multiple myeloma patients

OPTIMISMM Japanese Subgroup Analysis: Pomalidomide, Bortezomib, and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Safety and Efficacy of Elotuzumab with Lenalidomide/Dexamethasone for Multiple Myeloma in a Japanese Subpopulation Analysis of the Phase 3 Eloquent-2 Trial

Antileukemic

Improved survival outcomes and relative youthfulness of multiple myeloma patients with t(4;14) receiving novel agents are associated with poorer performance of the revised international staging system in a real aging society

Proposal of Progressive Adult Onset EBV-Associated Lymphoproliferative Disorder (PAEBV) as a Rapid-Onset Neoplastic Disease

Characteristics and Risk for Progression of Smoldering Multiple Myeloma: Japanese Nationwide Retrospective Survey

MM-004: A Phase 1, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, Efficacy, and Pharmacokinetics of Pomalidomide Alone or in Combination with Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma in Japan

Elranatamab in Combination with Daratumumab for Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 3 Magnetismm-5 Study Safety Lead-in Cohort

Subcutaneous Isatuximab Administration By an on-Body Delivery System (OBDS) in Combination with Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Phase 1b Expansion Study Results

Subcutaneous (SC) isatuximab administration by an on-body delivery system (OBDS) in combination with pomalidomide-dexamethasone (Pd) in patients with relapsed/refractory multiple myeloma (RRMM): Interim phase 1b study results

Evaluation of the Revised International Staging System in 400 Patients with Symptomatic Myeloma in a Japanese Clinical Setting

Clinical Impact of Cell-of-Origin and Double-Hit Signature of DLBCL in Japan

Efficacy and Safety of Zanubrutinib in Japanese Patients with Mature B-Cell Malignancies

DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase II study

Impact of Continuous and Maintenance Therapy on Survival Outcome in Patients with Newly Diagnosed Multiple Myeloma: A Multicenter Retrospective Collaborative Study of the Japanese Society of Myeloma

P-306 Final results of a Phase 1b study of subcutaneous isatuximab administration by an on-body delivery system (OBDS) plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma (RRMM)

Efficacy of Isatuximab with Pomalidomide and Dexamethasone in Elderly Patients with Relapsed/Refractory Multiple Myeloma: Icaria-MM Subgroup Analysis

Aktive Filter

Suchergebnisse filtern